Svas Biosana S.p.A., the Healthcare sector company, was revisited by a Wall Street analyst on September 29. Analyst from TP ICAP MIDCAP reiterated a Buy rating on the stock and has a €12.90 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TP ICAP (Europe) S.A. has given its Buy rating due to a combination of factors that highlight Svas Biosana S.p.A.’s strong financial performance and strategic growth initiatives. The company reported a significant increase in revenue for the first half of 2025, reaching €70.4 million, which marks a 21% year-over-year growth. This growth is attributed to strong organic momentum and successful integration of recent acquisitions in Serbia.
Furthermore, Svas Biosana’s EBITDA rose by 18.9% year-over-year, maintaining a stable margin of 13%, which underscores the company’s ability to manage growth while preserving profitability. The company’s strategic focus on expanding its geographic footprint, particularly in the Baltic and Balkan markets, and its effective cost management strategies have also contributed to its robust financial health. These factors, combined with the expected normalization of public receivables and full contribution from recent acquisitions in the second half of the year, provide confidence in the company’s ability to achieve its full-year targets.